Clinical Trial Update: Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab plus enobosarm in androgen receptor-positive metastatic triple-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Enobosarm (enobosarm)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Androgen Receptor Positive, Estrogen Receptor Negative | Phase 2 | Status: COMPLETED | Results posted: 2022-06-10